Vir Biotechnology (VIR) Accumulated Expenses (2018 - 2026)

Vir Biotechnology has disclosed Accumulated Expenses across 9 years of filings, most recently posting $68.1 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $68.1 million, down 34.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $68.1 million (down 34.59% YoY), and the FY2025 annual result was $83.0 million, down 15.74% from the prior year.
• Accumulated Expenses came in at $68.1 million for Q1 2026 at Vir Biotechnology, down from $83.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $489.1 million in Q4 2022 to a low of $7.7 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $83.0 million (2025), against an average of $130.8 million.
• Across the five-year window, Accumulated Expenses sank 89.01% in 2022 and jumped 5821.06% in 2023, its largest moves.
• Vir Biotechnology's Accumulated Expenses stood at $489.1 million in 2022, then tumbled by 78.69% to $104.2 million in 2023, then fell by 5.47% to $98.5 million in 2024, then fell by 15.74% to $83.0 million in 2025, then fell by 17.95% to $68.1 million in 2026.
• The last three Accumulated Expenses figures came in at $68.1 million (Q1 2026), $83.0 million (Q4 2025), and $68.4 million (Q3 2025), per Business Quant data.